Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGAVE Pilot study of octreotide for refractory bleeding from gastric antral vascular ectasia
NL-OMON21472Recruiting
- Sponsor
- Radboudumc
- Start
- Aug 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of octreotide in gastric antral vascular ectasia (GAVE) and refractory anemia (RA), sponsored by Radboudumc. Primary endpoint: Successful response. Started Aug 2020; status: recruiting.
02
Drugs
octreotide
03
Conditions
gastric antral vascular ectasia (GAVE)refractory anemia (RA)
Beyond the preview
Go deeper on NL-OMON21472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21472.